This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, S. Articles by Giacomini, K. M. Search for Related Content PubMed PubMed Citation Articles by Zhang, S. Articles by Giacomini, K. M.

Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity

Departments of ¹ Biopharmaceutical Sciences and ² Laboratory Medicine and Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California and ³ Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts

Requests for reprints: Kathleen M. Giacomini, Department of Biopharmaceutical Sciences, University of California at San Francisco, 1550 4th Street, San Francisco, CA 94158. Phone: 415-476-1936; Fax: 415-502-4322; E-mail: kathy.giacomini{at}ucsf.edu or Stephen J. Lippard, Department of Chemistry, Room 18-498, Massachusetts Institute of Technology, Cambridge, MA 02139. Phone: 617-253-1892; Fax: 617-258-8150; E-mail: lippard{at}mit.edu.

Although the platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin have similar DNA-binding properties, only oxaliplatin is active against colorectal tumors. The mechanisms for this tumor specificity of platinum-based compounds are poorly understood but could be related to differences in uptake. This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. The cytotoxicity of oxaliplatin was greater than that of cisplatin in six colon cancer cell lines [mean ± SE of IC₅₀ in the six cell lines, 3.9 ± 1.4 µmol/L (oxaliplatin) versus 11 ± 2.0 µmol/L (cisplatin)] but was reduced by an OCT inhibitor, cimetidine, to a level similar to, or even lower than that of, cisplatin (29 ± 11 µmol/L for oxaliplatin versus 19 ± 4.3 µmol/L for cisplatin). Structure-activity studies indicated that organic functionalities on nonleaving groups coordinated to platinum are critical for selective uptake by OCTs. These results indicate that OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity. They also strongly suggest that expression of OCTs in tumors should be investigated as markers for selecting specific platinum-based therapies in individual patients. The development of new anticancer drugs, specifically targeted to OCTs, represents a novel strategy for targeted drug therapy. The results of the present structure-activity studies indicate specific tactics for realizing this goal. (Cancer Res 2006; 66(17): 8847-57)

This article has been cited by other articles:

				S. Hu, Z. Chen, R. Franke, S. Orwick, M. Zhao, M. A. Rudek, A. Sparreboom, and S. D. Baker Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters Clin. Cancer Res., October 1, 2009; 15(19): 6062 - 6069. [Abstract] [Full Text] [PDF]

				G. Minuesa, C. Volk, M. Molina-Arcas, V. Gorboulev, I. Erkizia, P. Arndt, B. Clotet, M. Pastor-Anglada, H. Koepsell, and J. Martinez-Picado Transport of Lamivudine [(-)-{beta}-L-2',3'-Dideoxy-3'-thiacytidine] and High-Affinity Interaction of Nucleoside Reverse Transcriptase Inhibitors with Human Organic Cation Transporters 1, 2, and 3 J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 252 - 261. [Abstract] [Full Text] [PDF]

				T. Minematsu, M. Iwai, K. Sugimoto, N. Shirai, T. Nakahara, T. Usui, and H. Kamimura Carrier-Mediated Uptake of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small-Molecule Survivin Suppressant, into Human Solid Tumor and Lymphoma Cells Drug Metab. Dispos., March 1, 2009; 37(3): 619 - 628. [Abstract] [Full Text] [PDF]

				V. Shnitsar, R. Eckardt, S. Gupta, J. Grottker, G. A. Muller, H. Koepsell, G. Burckhardt, and Y. Hagos Expression of Human Organic Cation Transporter 3 in Kidney Carcinoma Cell Lines Increases Chemosensitivity to Melphalan, Irinotecan, and Vincristine Cancer Res., February 15, 2009; 69(4): 1494 - 1501. [Abstract] [Full Text] [PDF]

				X. Ming, W. Ju, H. Wu, R. R. Tidwell, J. E. Hall, and D. R. Thakker Transport of Dicationic Drugs Pentamidine and Furamidine by Human Organic Cation Transporters Drug Metab. Dispos., February 1, 2009; 37(2): 424 - 430. [Abstract] [Full Text] [PDF]

				S. Yokoo, S. Masuda, A. Yonezawa, T. Terada, T. Katsura, and K.-i. Inui Significance of Organic Cation Transporter 3 (SLC22A3) Expression for the Cytotoxic Effect of Oxaliplatin in Colorectal Cancer Drug Metab. Dispos., November 1, 2008; 36(11): 2299 - 2306. [Abstract] [Full Text] [PDF]

				M. Okabe, G. Szakacs, M. A. Reimers, T. Suzuki, M. D. Hall, T. Abe, J. N. Weinstein, and M. M. Gottesman Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters Mol. Cancer Ther., September 1, 2008; 7(9): 3081 - 3091. [Abstract] [Full Text] [PDF]

				K. S. Lovejoy, R. C. Todd, S. Zhang, M. S. McCormick, J. A. D'Aquino, J. T. Reardon, A. Sancar, K. M. Giacomini, and S. J. Lippard cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects PNAS, July 1, 2008; 105(26): 8902 - 8907. [Abstract] [Full Text] [PDF]

				K. K. Filipski, W. J. Loos, J. Verweij, and A. Sparreboom Interaction of Cisplatin with the Human Organic Cation Transporter 2 Clin. Cancer Res., June 15, 2008; 14(12): 3875 - 3880. [Abstract] [Full Text] [PDF]

				G. Minuesa, S. Purcet, I. Erkizia, M. Molina-Arcas, M. Bofill, N. Izquierdo-Useros, F. J. Casado, B. Clotet, M. Pastor-Anglada, and J. Martinez-Picado Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 558 - 567. [Abstract] [Full Text] [PDF]

				Y. Chen, S. Zhang, M. Sorani, and K. M. Giacomini Transport of Paraquat by Human Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Family J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 695 - 700. [Abstract] [Full Text] [PDF]